

1 **Plasmin Cleavage of Beta-2-Glycoprotein I Alters its Structure and Ability** 2 **to Bind to Pathogenic Antibodies**

3
4 Hannah F. Bradford^{2*}, Christophe J. Lalaurie^{1*}, Jayesh Gor³, Xin Gao³, Charis Pericleous⁴, Stephen J. Perkins³,
5 Hannah Britt³, Konstantinos Thalassinos^{3,7}, Ian Giles⁵, Anisur Rahman⁵, Mihaela Delcea⁶, Paul A. Dalby¹, Thomas
6 C.R. McDonnell^{1‡},

7
8 From the

9 ¹ Biochemical Engineering, University College London, Bernard Katz Building, Gordon Street,
10 London, WC1H 0AH, UK,

11 ² Division of Infection and Immunity and Institute of Immunity and Transplantation, Royal Free
12 Hospital, University College London, London, NW3 2PP, United Kingdom

13 ³ Institute of Structural and Molecular Biology, Division of Biosciences, University College London,
14 London, WC1E 6BT, United Kingdom

15 ⁴ National Heart and Lung Institute, Imperial College London, London, UK.

16 ⁵ Centre for Rheumatology, Division of Medicine, University College London, London, UK.

17 ⁶ Department of Biophysical Chemistry, Institute of Biochemistry, University of Greifswald, 17489
18 Greifswald, Germany.

19 ⁷ Institute of Structural and Molecular Biology, Birkbeck College, University of London, London,
20 WC1E 7HX, United Kingdom

21
22 * **Shared 1st Authorship**

23
24 **Running Title:** Plasmin Cleaved β 2GPI Reveals Novel Structure and Binding.

25
26 ‡ Author to whom correspondence should be addressed (Tel: 020 3108 2174; Email:
27 thomas.mcdonnell.11@ucl.ac.uk).

28
29 **Keywords:** β 2-Glycoprotein I, Plasmin, Cleavage, Structural Change, Autoantigens
30

31
32 **Abstract**

33 Beta-2-Glycoprotein I (β 2GPI) is the main autoantigenic target of antiphospholipid syndrome
34 (APS) with antibodies leading to clinical manifestations. There are two known structural isomers of
35 β 2GPI, a J shape and a circular shaped one. The transition between these structures is incompletely
36 understood, with the functional implications unknown. β 2GPI is a substrate of the protease plasmin,
37 which cleaves within the fifth domain of β 2GPI leading to altered cellular binding. Very little is currently
38 known regarding the structure and function of this protein variant. We present the first comprehensive
39 structural characterisation plasmin-clipped β 2GPI and the associated implications for pathogenic antibody
40 binding to this protein.

41 **Methods**

42 β 2GPI was purified using a novel acid-free process from healthy control plasma and cleaved with
43 plasmin. Cleavage was confirmed by SDS-PAGE. Structural characterisation was undertaken using
44 dynamic light scattering (DLS), small angle X-ray scattering (SAXS), ion mobility mass spectrometry
45 (IMMS) and molecular dynamics simulation (MD). Activity was tested using inhibition of β 2GPI ELISAs
46 with patient samples and cleaved β 2GPI in the fluid phase and cellular binding by flow cytometry using
47 HUVEC cells.

48 **Results**

49 DLS revealed a significantly smaller hydrodynamic radius for plasmin-clipped β 2GPI ($p=0.0043$).
50 SAXS and MD analysis indicated a novel S-like structure of β 2GPI only present in the plasmin-clipped
51 sample whilst IMMS showed a different structure distributions in plasmin clipped compared to non-
52 clipped B2GPI. The increased binding of autoantibodies was shown for plasmin-clipped β 2GPI
53 ($p=0.056$), implying a greater exposure of pathogenic epitopes following cleavage.

54 **Conclusions:**

55 Cleavage of β 2GPI by plasmin results in the production of a unique S-shaped structural
56 conformation and higher patient antibody binding. This novel structure may explain the loss of binding to
57 phospholipids and increase in anti-angiogenic potential described previously for plasmin-clipped β 2GPI.
58
59
60

61 Introduction

62 Beta-2-Glycoprotein I (β 2GPI) is a serum glycoprotein of approximately 50 kDa, comprised of
63 four structurally similar domains (DI-DIV) and a structurally distinct fifth domain (DV) which are
64 arranged in a single chain like beads on a string. β 2GPI circulates at a concentration of approximately
65 200 μ g/ml and has to date been proposed to exist in two possible structures an “open” J-shaped and
66 “circular” O-shaped structure (1). The first four domains are typical members of the short complement
67 regulator (SCR) superfamily, termed domains DI-DIV while the C terminal domain (DV) contains lysine-
68 rich regions on the surface, responsible for cellular binding. The activities of β 2GPI are widely varying
69 from angiogenesis to complement activation, whilst the structure of β 2GPI is hypothesised to have
70 significant implications for the activity of the molecule based on the assumption that, in the circular form,
71 various motifs are hidden from solvent, thus preventing interactions with expected binding partners (1).

72
73 In circulation, β 2GPI has a number of contrasting functions and is almost unique (2) in being
74 capable of both up- and down-regulation of activation of the complement and coagulation cascades. It is
75 incompletely understood how these opposing functions are balanced; however, it has been hypothesised
76 that regulation between these opposing functions is through structural restriction. Therefore, the structure
77 of β 2GPI, and the factors that modify it, are crucial to fully understand its activity and function.

78 The structure of β 2GPI is complex, and as previously mentioned it can form a linear (J-shaped;
79 PDB ID: 1C1Z) or a circular (O-shaped) structure. However, it has been suggested that β 2GPI can also
80 form an intermediate or alternative structure which is S-shaped, as first shown by Hammel et al using
81 small angle X-ray scattering (SAXS) (3-7). The regulation of its structure is incompletely understood,
82 however, several factors have been shown *in vitro* to trigger structural change, including changes in pH,
83 salt concentration (1), disulphide reduction (8) and lysine acetylation (9). Genetic manipulations to delete
84 a disulphide to mimic the impact of reduction (10), although less clinically relevant, has also been shown
85 by SAXS to alter β 2GPI structure reverting to the J shape rather than the O-shape. Most recently Kumar
86 et al. studied the potential for a shift in serum concentration to purely linear β 2GPI, highlighting the
87 potential for this equilibrium to be shifted and altering the exposure of protein motifs (11).

88 The role of β 2GPI in complement and coagulation is further complicated by the fact that it is a
89 substrate for plasmin. β 2GPI plays a role in the conversion of plasminogen to plasmin, facilitating this
90 through the binding of the fifth domain to plasminogen (12). The cleavage of β 2GPI by plasmin takes
91 place between the eighth and ninth amino acids from the C-terminus, yielding a peptide by-product of
92 eight amino acids, and a shortened fifth domain. This modification of β 2GPI prevents its binding to
93 plasminogen and thus slows the conversion of plasminogen to plasmin in the absence of other cofactors
94 for plasminogen cleavage (13). This loss of activity suggests a change in binding and function after
95 cleavage, which has been shown in other studies (14-16).

96
97 Plasmin-clipped β 2GPI can act as an inhibitor of angiogenesis (14), a function much less
98 prominent in the non-cleaved form. Furthermore, the cleavage of β 2GPI leads to increased cardiac
99 manifestations in neonatal lupus *in vivo* (17) due to the loss of the binding site for Ro60, an autoantigen
100 linked to other autoimmune disorders which functions as an RNA scavenger. β 2GPI binds in the central
101 pore of Ro60, preventing the binding of anti-Ro60 autoantibodies. The Anti-Ro60/Ro60 complex induces
102 foetal heart block, therefore β 2GPI binding rescues this phenotype, plasmin cleavage disrupts the 5th
103 domain (DV) of β 2GPI and thus prevents binding to Ro60. Plasmin-clipped β 2GPI has also been linked
104 to cerebral infarction in antiphospholipid syndrome (APS) patients (16), whilst un-cleaved β 2GPI has not
105 been shown to have these same effects. Notably, Itoh et al. (18) showed increased levels of plasmin-
106 clipped B2GPI in leukaemia patients, specifically associated with increased thrombosis. Despite this
107 physiological role, the structures adopted by plasmin-clipped β 2GPI are yet to be elucidated.

109 β 2GPI is also the main auto-antigenic target of Antiphospholipid Syndrome (APS). APS is an
110 autoimmune clotting disorder which is the leading cause of strokes under 50 years old and recurrent
111 miscarriage. Patients routinely develop autoantibodies to Cardiolipin and β 2GPI, both of which feature in
112 diagnostic clinical criteria, however, a number of non-criteria antibodies also exist. Several studies have
113 placed significant importance on anti-B2GPI autoantibodies, both diagnostically and mechanistically, as
114 these antibodies are pathogenic in a range of mouse models (19,20). There is a polyclonal response with
115 anti-B2GPI autoantibodies formed against a wide range of epitopes, however the two dominant sites for
116 autoreactivity are DI and DV. Within the 1st domain, a cryptic neo-epitope has been defined (R39-G43)
117 to which the most pathogenic anti- β 2GPI antibodies are formed, which have been shown to be thrombotic
118 both *in vitro* and *in vivo*. Reversal agents which specifically target DI (21,22) have reduced clotting in *in*
119 *vitro* functional assays and in both acute and chronic APS mouse models (23-25). The formation of the
120 anti- β 2GPI/ β 2GPI complex can trigger thrombosis in several ways, and notably in mouse models of
121 APS, complement is also required to develop thrombosis, as C3^{-/-} phenotypes rescue the mouse from
122 thrombosis (26). The influence of β 2GPI structure in APS is less well known, with few structural methods
123 applied to β 2GPI from patient serum. The circular form of B2GPI, traditionally hypothesised to be
124 dominant in serum, theoretically hides both the DI and DV epitopes, implying the requirement of an open
125 β 2GPI form for antibody complex formation and thus disease progression (27). This has been refuted by
126 recent research (11). The role of plasmin cleavage in APS is even less well studied and given the role of
127 β 2GPI in regulating both complement and coagulation, and the role of these cascades in APS, a naturally
128 occurring cleavage by those cascades on a regulator is interesting. For example, during thrombosis β 2GPI
129 may act as a co-factor increasing this process, in doing so also by proxy activating complement and
130 cleaving β 2GPI which then loses the ability to regulate other functions. As such it is vital to understand
131 the structures formed by β 2GPI post plasmin cleavage to study the effect of plasmin clipped β 2GPI in
132 APS.

133
134 Here, we use a combination of biophysical and *in silico* techniques to characterise the structures of
135 β 2GPI generated by plasmin cleavage, and in order to gain a better understanding of how the structures
136 are formed and stabilised in solution. The identification of novel structures may lead to an increased
137 understanding of autoantibody generation, thrombosis formation and how the structure of β 2GPI affects
138 its role in various bodily systems.

139 **Methods**

140 ***Purification of β 2GPI***

141
142 Plasma was separated by SepMate (StemCell, Cambridge, UK). 50 ml of venous blood (collected
143 in 10 ml sodium heparin vacutainers) was diluted 1:1 with RPMI 1640 media, meanwhile, 15 ml of
144 Ficoll-Paque was dispensed into a 50 ml SepMate tube and 33 ml of diluted blood gently layered on top.
145 Samples were centrifuged at $1,200 \times g$ for 10 minutes and the top layer was poured into a 50 ml tube and
146 re-spun for 5 minutes at $500 \times g$. Supernatant was again poured off and stored at -20°C before use.
147 β 2GPI was precipitated using a polyethylene glycol (PEG) precipitation method as previously described
148 (28). Briefly, plasma was diluted 1:4 with 10 mM sodium phosphate (pH 6.8) and 40% PEG 4000 (VWR,
149 Lutterworth, UK) in 10 mM sodium phosphate (pH 6.8) was cooled on ice. The 40% PEG 4000 solution
150 was then added drop wise to the diluted plasma, whilst mixing on a magnetic plate. For 35 ml of plasma,
151 12.5 ml of 10 mM sodium phosphate was added and a further 75 ml of PEG 4000 to a final concentration
152 of PEG 4000 of 25%. This mix was then incubated at 4°C for 30 minutes. Precipitate was collected in
153 50 ml Falcon tubes by centrifugation at $3000 \times g$ for 30 minutes. Supernatant was discarded and
154 precipitate was re-solubilised in 20 mM Tris pH 8.0, 30 mM NaCl at an appropriate volume. This was
155 centrifuged for 30 minutes at $3000 \times g$ to remove insoluble matter and the supernatant taken forward to
156 purification. Purification was initially across 3×1 ml Heparin FF columns (Cytiva, Buckingham, UK) at
157 a flow rate of 1 ml/min. Samples were pump loaded and the pressure was kept below 0.3 mPa. Once
158

159 loaded the column was washed with 30 ml of 20 mM Tris 30 mM NaCl pH 8.0. A gradient was used to
160 purify β 2GPI between 30 mM NaCl and 350 mM NaCl starting at 0% and finishing at 100% across 1
161 hour, 5 ml fractions were collected and checked for β 2GPI by SDS-PAGE. Samples were then quickly
162 dialysed (centrifugal concentration) or diluted as appropriate to 50 mM sodium acetate, 50 mM NaCl, pH
163 4.5 (Buffer A), and loaded on a 5 ml SPHP column (Cytiva, Buckingham, UK). Samples were eluted
164 across a gradient of 40-60% Buffer B (50 mM Sodium acetate, 650 mM NaCl, pH 5.3) across 1 hour,
165 peaks were checked for β 2GPI by SDS-PAGE. Peaks containing β 2GPI were pooled and purified by size
166 exclusion chromatography (16/600, Superdex 200) in phosphate saline buffer (PBS) using a single
167 isocratic wash. Samples were quantified by bicinchoninic acid assay using a bovine serum albumin
168 standard curve.

169 **Cleavage of β 2GPI**

171 Purified β 2GPI was cleaved overnight using plasmin (Cambridge Biosciences, Cambridge, UK) at
172 a 1:1 ratio in cleavage buffer (100 mM Tris, 0.02 M NaCl, 0.3 mM CaCl_2 , pH 7.5). Volumes were made
173 up to 500 μ l and left rotating overnight at 37 °C. Cleavage was confirmed through reduction studies.
174 10 μ l of reaction mix was incubated with 0.05 M Tris(2-carboxyethyl)phosphine hydrochloride or 0.1 M
175 dithiothreitol for 15 minutes at 95 °C before being run on a 4-12% SDS-PAGE BOLT gel (Invitrogen,
176 Waltham Massachusetts, USA) for 32 minutes at 165 volts. Samples which did not alter their migration
177 under reduction were confirmed to be successfully cleaved.

179 **Dynamic Light Scattering**

180 The hydrodynamic diameter of β 2GPI at 0.1 mg/ml was measured using a Zetasizer Nano-ZS
181 (Malvern Instruments, Herrenberg, Germany). Samples were prepared by filtration (0.2 μ M) and
182 centrifugation (16,000 \times g, 10 minutes) to reduce potential aggregate formation. Measurements were
183 taken with a detector angle of 90° and a refractive index of 0.01. The pedestal height was allowed to float
184 during measurements ensuring maximal signal. A total of three measurements per protein (six runs with a
185 duration of 10 s per measurement) were obtained and data averaged. Data were analysed using Microsoft
186 Excel and statistical differences were derived using GraphPad Prism 7.0.

188 **Small Angle X-ray Scattering**

189 X-ray scattering data were obtained during a single beam session on Instrument B21 at the
190 Diamond Light Source at the Harwell Science and Innovation Campus in Oxfordshire, operating with a
191 ring energy of 3 GeV and a beamline operational energy of 12.4 keV (47). A PILATUS 2M detector with
192 a resolution of 1475 \times 1679 pixels (pixel size of 172 \times 172 μ m) was used with a sample-to-detector
193 distance of 4.01 m giving a Q range from 0.04 to 4 nm^{-1} (where $Q = 4 \pi \sin \theta / \lambda$; 2θ = scattering angle; λ =
194 wavelength). The β 2GPI samples, at concentrations between 1.5 mg/ml and 0.1 mg/ml, in buffer were
195 loaded onto a 96-well plate that was placed into an EMBL Arinax sample holder (48, 49). This
196 measurement condition showed the β 2GPI molecule as a hydrated structure in a high positive solute-
197 solvent contrast (18). An automatic sampler injected 30 μ l of sample from the well plate into a
198 temperature-controlled quartz cell capillary with a diameter of 1.5 mm. Datasets of 30 frames with a
199 frame exposure time of 1 s each were acquired in duplicate as a control of reproducibility. Checks during
200 data acquisition confirmed the absence of radiation damage. Buffer subtraction was carried out
201 automatically. Analysis of Guinier, P(r) and Kratky plots were carried out using ScatterIV and GraphPad
202 Prism 7.0.

204 **Molecular Dynamics**

205 The crystal structure coordinates of β 2GPI (PDB ID: 1c1z) were prepared for molecular dynamics
206 using Glycan Reader and Modeler (29-32) at the CHARMM-GUI website ([http://www.charmm-
207 gui.org/](http://www.charmm-gui.org/)). Protonable residues were edited on CHARMM-GUI. Modifications to take account of the
208 plasmin clipping of β 2GPI were carried out *in silico* through the deletion of amino acids 318-326 in

209 Pymol. Both plasmin-clipped and healthy control (non-clipped) B2GPI had full glycan chains added in
210 accordance with the four biantennary glycans detected by Kondo et al (2009).

211
212 The TIP3P model was used for explicit water molecules. The cubic system size was determined to
213 give at least 10 Å from the protein in each axis, and 0.15 M NaCl was added. The CHARMM36 force
214 field was used (33,34), and all calculations were performed at 303.15 K. The particle mesh Ewald
215 algorithm was applied to calculate electrostatic forces, and the van der Waals interactions were smoothly
216 switched off at 10 Å by a force-switching function (35). A time step of 2 fs was used in all simulations.
217 Initially, each system was shortly equilibrated in constant particle number, volume, and temperature
218 (NVT) condition using CHARMM36 (36). To assure gradual equilibration of the system, positional
219 restraints for backbone and side chain heavy atoms were applied and the restraint forces were gradually
220 reduced during the equilibration. Each system was further simulated for 100 ns using the CHARMM36
221 force field on the high-performance cluster, Kathleen, at University College London using NAMD (37).
222 For the production NPT simulation, the Langevin coupling coefficient was set to 1 ps⁻¹ and a Nosé-
223 Hoover Langevin-piston (38,39) was used to maintain constant pressure (1 bar) with a piston period of 50
224 fs and a piston decay of 25 fs. The time step was 2 fs and trajectories were saved every 100 ps. The
225 electrostatic interactions were updated every 20 fs. The short-range non-bonded and electrostatic
226 interactions were calculated with a cut off of 12 Å. SHAKE was used to constrain all bonds involving
227 hydrogen atoms. Convergence of the simulations for all systems was checked through the comparison of
228 average RMSD using VMD (40). Each simulation was repeated three times and the data were averaged
229 for analysis. These were carried out on Kathleen (High Performance Computer at UCL, based on Intel
230 Xeon Gold Processors).

231 ***Inhibition ELISA***

232 Inhibition ELISAs were performed as previously described (23). Briefly, serum samples with
233 historical positivity for anti-β2GPI antibodies were tested in an anti-β2GPI ELISA. Maxisorb plates
234 (ThermoFischer, Waltham Massachusetts, USA) were coated with 2 µg/ml of β2GPI (Enzyme Research
235 Laboratories, Swansea, UK) overnight at 4 °C before being blocked with 2% BSA/PBS (Sigma, St Louis,
236 Massachusetts, USA) for 1 hour at 37 °C (150 µl per well). Plates were washed with PBS Tween (0.1%)
237 three times before application of serum at a dilution of 1:50 in 1% bovine serum albumin in PBS for 1
238 hour at room temperature (50 µl per well). Plates were again washed and anti-human IgG conjugated to
239 horse radish peroxidase (HRP, Gillingham, Sigma) was applied at a titration of 1:2000. The plate was
240 again incubated at room temperature for 1 hour. Plates were washed and 100 µl of 3,3', 5,5'-
241 tetramethylbenzidine (KPL, Gaithsburg, Maryland, USA) added and incubated for 15 minutes at room
242 temperature before being stopped with 100 µl of stop solution (1N, KPL, Gaithsburg, Maryland, USA).
243 Plates were read by absorbance at 450 nm, in a plate reader (Tecan Infinite PRO+, Tecan, Männedorf,
244 Switzerland). Inhibition assays were performed identically with the exception of a two-hour pre-
245 incubation of serum samples with either healthy control (non-clipped) β2GPI or plasmin-clipped β2GPI at
246 room temperature before application of sample to the plate. Inhibition was calculated by comparing
247 samples in the absence and in the presence of inhibitor on a single plate.

248 ***Native PAGE***

249
250 Non-cleaved protein was loaded at 0.6µg, 1.2 µg, 2.4 µg and 5µg in Native loading buffer
251 (Invitrogen). Plasmin-clipped β2GPI was loaded at 5µg diluted in native loading buffer (Invitrogen).
252 Samples were loaded into a 10% Tris-Glycine NATIVE Page Gel (Invitrogen) and run in Tris-Glycine
253 NATIVE Running Buffer at 150v, variable milliamps for 5 hours at room temperature. Gels transferred to
254 PVDF membranes using the BioRad Turboblotter (7 minutes, 10V Mixed Protocol) and blocked with
255 10% skimmed milk in PBST (0.5%). Membrane was exposed for fluorescence (Thermofisher iBright) for
256 Cy3 and Cy5. Membranes were then incubated with anti-B2GPI antibody (PA-1-74015, Thermofisher)
257 overnight. Membranes were washed with 10% milk in 0.5% PBST for 3 hour (3x20 minutes) and then

259 incubated for 1 hour rolling at room temperature with anti-goat antibody conjugated to HRP (1:1000,
260 DAKO). Finally, membranes were washed with PBST (0.5%) and exposed using Amersham Prime ECL
261 (Amersham) on an Amersham ImageQuant 800 (Amersham, GE Healthcare).

262 ***Fluorescent Labelling and flow cytometry***

263 Glycan labelling of β 2GPI was carried out using the N Glycan Labelling Kit (BioTechne). Non-
264 clipped B2GPI was labelled using 1 μ l Neuraminidase, 1 μ l StGal6 and 1 μ l of label per 5 μ g of protein,
265 incubated at 37°C for 1 hour. Clipped β 2GPI was labelled using 2 μ l Neuraminidase, 2 μ l StGal6 and 5 μ l
266 of label per 5 μ g of protein, incubated at 37°C for 1 hour. Both labelled proteins were stored at +4°C in the
267 dark. Plasmin-clipped β 2GPI was labelled with Cy3 whilst non-clipped was labelled with Cy5. Labelled
268 clipped and non-clipped β 2GPI were incubated with human umbilical vein endothelial cells (HUVEC) for
269 2 hours at 37°C. Cells were plated at 500,000/well with 2 μ g of fluorescently labelled β 2GPI. Cells were
270 incubated with Live/Dead Blue viability Dye (ThermoFisher) for 20 minutes in the dark at room
271 temperature. Cells were then stained with CD105-BV421 (BioLegend, 43A3) for 30 minutes at 4°C
272 to allow identification of HUVEC, then incubated in fixation buffer (ThermoFisher) for 15 minutes at 4°C
273 in the dark. Percentages of cells positive for β 2GPI were then compared between plasmin-clipped β 2GPI
274 and non-clipped β 2GPI. Samples were acquired on a Fortessa X20 flow cytometer (BD). Data were
275 analysed by FlowJo (v10).

276 ***Ion Mobility Mass Spectrometry***

277 Ion Mobility Mass Spectrometry was carried out in the Thalassinos Laboratory at UCL. Protein
278 samples were buffer exchanged into 10 mM ammonium acetate using an Amicon 30 kDa MWCO filter
279 for analysis on a SELECT SERIES Cyclic IMS QToF (Waters Corp.) (41,42). Samples were direct
280 infused into the instrument at a concentration of 2.5 μ M using nano electrospray capillaries prepared in
281 house using a Flaming-Brown P97 micropipette puller, and gold-coated with a Quorum Q150RS sputter
282 coater. Data were processed using UniDec and MassLynx v4.2.

RESULTS

Validation of cleavage of β 2GPI by plasmin

β 2GPI was cleaved successfully overnight (16 hours, 1:1 ratio) yielding approx. 50% cleaved protein. Confirmation of cleavage was achieved by SDS-PAGE (Figure 1A) and native PAGE/Western Blot (Figure 1B). In the native gel/western the plasmin clipped protein forms a wider smear with a higher mobility under native conditions, suggesting that it is more flexible and potentially more compact compared to the non-cleaved linear structure. The affected sites from cleavage are modelled in Figure 2. Protein was purified from plasmin mix using ion exchange chromatography, showing a shift in affinity under cation exchange conditions, eluting at a lower conductivity. This confirmed cleavage and enabled good separation of cleaved and non-cleaved β 2GPI (not shown).

Native IMMS Data Confirm Altered Structure

Analysis of the non-clipped and clipped β 2GPI by means of native ion mobility mass spectrometry revealed differences between the two samples, both in the mass spectrometry and ion mobility dimensions. As seen in Figure 3A, multiple peaks can be seen for each charge state due to glycosylation. While this is true for both samples, for the plasmin clipped sample there is a shift toward the lower charge states being more prominent which is indicative of a more compact / folded conformation. This is shown further in the arrival time distributions obtained from the IM analysis. IM separates ions based on their interaction with a buffer gas as they travel through a mobility cell under the influence of a weak electric field. The time an ion takes to traverse the IM cell is related to its charge and rotationally averaged collision cross section (CCS or Ω), the latter being a physical quantity related to the overall shape (43). For ions of the same charge state, the more compact species will therefore have a faster arrival time distribution (ATD) than an extended one. While the plasmin-clipped protein has one peak in the ATD, the non-clipped version has an additional, later arriving peak illustrating that the protein co-exists in two broad conformers, a compact and an extended one.

Flow Cytometry Shows Consistent Activity

Non-cleaved and plasmin-clipped β 2GPI were conjugated to Cy5 and Cy3 respectively and incubated with human umbilical vein endothelial cells (HUVEC) for 2 hours at 37°C. HUVEC were stained with CD105-BV421 for identification by flow cytometry. Significantly higher frequencies of CD105⁺ HUVEC ($P < 0.05$) were positive for non-clipped β 2GPI (30%) compared to plasmin-clipped β 2GPI (<5%) consistent with findings from other studies. This confirmed that cleavage has been successful and suggested that fluorophore labelling has not altered the physical function of the protein facilitating binding of the protein to cellular surfaces.

ELISA assays

Activities of non-cleaved and plasmin-clipped β 2GPI were measured using in-solution inhibition assays. In Figure 4A the y-axis shows inhibition, defined as the percentage reduction in binding in the presence of inhibitor (clipped or non-clipped β 2GPI) compared to absence of inhibitor. The mean inhibition was 14.9% (SD 8.9%) for plasmin-clipped β 2GPI compared to 9.4% (SD 9.1%) for non-clipped β 2GPI ($p = 0.056$). This suggests that the structural alteration may influence the ability of β 2GPI to bind pathogenic antibodies in favour of higher binding for plasmin-clipped β 2GPI, potentially due to changes in surface exposure.

Altered structural profiles after plasmin cleavage revealed by DLS

DLS measurements showed a significant difference ($p = 0.039$) in hydrodynamic radius between the plasmin-clipped β 2GPI ($n = 6$, 7.8 nm) and non-clipped β 2GPI ($n = 3$, 8.8 nm), Figure 4B. This difference of approximately 1nm may be explained by a slightly different structural profile, with a smaller hydrodynamic radius accounting for a more compact form. This corresponds to the changes seen by Native PAGE.

SAXS comparison of plasmin-clipped and healthy control (HC, non-clipped) β 2GPI

Plasmin-clipped and non clipped β 2GPI were imaged at the Diamond Light Source Facility in the Harwell science campus (UK) for SAXS analysis. A range of concentrations from 1.5 mg/ml to 0.2 mg/ml were imaged with optimal comparative data being obtained for concentrations of 1 mg/ml. Buffer was subtracted automatically post-normalisation, and no difference in intensity was seen between the two proteins (Figure 5A).

Guinier analysis was carried out on both HC and plasmin-clipped β 2GPI curves identifying a single linear region (Figure 5B). The Q . R_G limits were similar between both proteins with the HC Q -range from 0.446 \AA^{-2} to 1.287 \AA^{-2} whilst plasmin-clipped was 0.571 \AA^{-2} to 1.297 \AA^{-2} . These ranges were selected as they gave the most linear fit and the inclusion of values up to a Q . R_G of 1.3 is in line to include globular, disk- and rod-shaped objects. The R_g was calculated to have values of 40.9 \AA and 40.3 \AA , respectively for HC and plasmin-clipped β 2GPI.

Pair-distance distribution function analysis $P(r)$ was used to provide structural information in real space, where the largest Q value was limited to 0.13 nm^{-1} . D_{max} was set to 118 nm for both proteins by trial and error, giving the smoothest descent to zero and some slight aggregation was seen in the plasmin-clipped sample at very low Q values, however, this region was before the Q values used in the Guinier analysis. R_G values from the $P(r)$ analysis were smaller than for the Guinier analysis with healthy control (non-clipped) calculated at 38.4 \AA whilst plasmin-clipped was calculated at 37.6 \AA . These values are within 10% of the Guinier analysis values and predicts a smaller R_G for plasmin-clipped β 2GPI, which is consistent with the DLS data. The peaks seen in the $P(r)$ analysis are formed by the most frequently occurring atomic distances within the structure, the dominant peak in both healthy control (non-clipped) and plasmin-clipped β 2GPI occurs between 30 and 40 \AA , whilst the shape of the peak suggests a long rod shape. The maximum length of the protein (L) was calculated using the $P(r)$ function identifying the shape as a long rod and solving the equation for L (44):

$$L = R_G / \sqrt{\frac{1}{12}}$$

This gave a length of 132.8 \AA for HC β 2GPI and 130.2 \AA for plasmin-clipped β 2GPI, again suggesting a smaller size for plasmin-clipped β 2GPI. Analysis of Kratky plots (Figure 5C) showed a more defined maximum for the plasmin-clipped protein (green) compared to healthy control (non-clipped) β 2GPI (black), whilst a dimensionless Kratky plot showed both proteins had a multidomain profile (Figure 5D). This suggested a less linear, although not a fully compact globular protein form. This may also point to increased flexibility in the plasmin-clipped β 2GPI.

Further to this, the $P(r)$ function (Figure 5E) showed the characteristics of an elongated protein, with an initially well-defined peak before a tail around 75 \AA . Although both samples showed this profile, a difference was seen in the height of the peaks, suggesting that although the two proteins were extended, they were non-identical in structure.

Molecular Dynamics

To generate potential model conformations that could explain the SAXS data, three 100 ns repeats of molecular dynamics simulations were run. These were based on the crystal structure of β 2GPI (PDB ID: 1c1z) and used a simulated temperature of 313 K . These simulations were then used as sources of β 2GPI structures to generate theoretical SAXS curves, to identify those conformers which fit best to the SAXS data (45,46). SASSIE was used to generate the theoretical curves from structures, which were then analysed for best fit to experimental data using a Chi Squared filter. The top 100 structures were

382 identified and plotted in Figure 6. All structures associated with healthy control (non-clipped) β 2GPI
383 (bottom) had a smaller range of radius of gyration (R_G) than for the plasmin-clipped (top). The top 100
384 structures, highlighted in red, were significantly different in their R_G values ($p=0.0001$) with those for
385 healthy control (non-clipped) ranging from 42.3 to 46.7 nm, whilst those for plasmin-clipped ranged from
386 38.9 to 43.6 nm. This reflects the smaller values for plasmin-clipped seen in the DLS data.
387

388 These top 100 hits were aligned and overlaid to evaluate whether there was a single consistent
389 structure associated with either the healthy control (non-clipped) or plasmin-clipped β 2GPI. As can be
390 seen in Figure 6, healthy control (non-clipped) (blue) had a consistently extended J-shaped linear form of
391 the structure, as has been observed previously by a number of methods including crystal structures (5),
392 AFM (47) and SAXS (48). By contrast, the plasmin-clipped β 2GPI (Beige) consistently gave a novel S-
393 shaped linear form of the structure, which was therefore more compact than the J-form. When overlaid
394 with each other and aligned based on the 3rd and 4th domains (DIII, DIV), there was a clear and significant
395 divergence in the position of the 1st 2 domains (DI, DII) (Figure 6C/D). The single best-fit models were
396 then overlaid to show more clearly the difference (Figure 6C/D) between the two structures. The R_G was
397 also significantly different with smaller values seen in the plasmin-clipped, as shown in DLS confirming
398 the SAXS and MD were consistent with other laboratory processes (Figure 6E).
399

400 Applying Principal Component Analysis (PCA) to the top 100 conformations of each of healthy
401 control (non-clipped) and plasmin-clipped β 2GPI showed a clear difference, with their structures
402 clustering independently when using the hclust function in R (hierarchical, complete linkage) (Figure 7C)
403 this was further demonstrated using aligned structures of best fit in Figure 7A and Figure 7B. To avoid
404 clustering being influenced by the removal of 8 amino acids, all frames were trimmed to contain identical
405 constructs, the proteins aligned using all carbon atoms before the PCA was carried out. Further to this,
406 highlighting the DI epitope on a space model (Figure 7E) shows that the epitope has a potentially very
407 different solvent exposure in the plasmin-clipped structure. Analysis of the entire simulations
408 independently of the SAXS data showed a significantly increased RMSD for the plasmin-clipped β 2GPI
409 over time. At the amino acid level, the regions of greatest movement as measured by RMSD, were found
410 in the 1st and 5th domains (DI, DV, Figure 8). This suggests that the switch into this novel S-shaped
411 structure after cleavage by plasmin, may be associated with an overall increase in flexibility within the
412 protein as the terminal domains are both moving in opposition to one another. Furthermore, when
413 clustering all conformations and not just the frames extracted from SAXS analysis, and investigating the
414 effect of each amino acid on the principal components (PCs), the 5th domain (DV) drives the separation in
415 the 1st 5 PCs (Supplementary Figure 1) suggesting this is driving the most significant structural change.
416

417 Plotting the other variables (RMSD/ R_G) for the top 100 fitted structures from the SAXS analysis
418 identifies structures with a high RMSD and a low R_G suggesting they are flexible but compact, which
419 links with the initial data from the DLS and Native PAGE (Supplementary Figure 1C). Furthermore these
420 structures are found in the 1st cluster predominantly which occurs early in the simulations, suggesting that
421 they are quickly adopted and potentially therefore low energy.
422

423 DISCUSSION

424

425 The role of plasmin-clipped β 2GPI is still a mystery in the context of APS with little known about
426 its structure and its function. It has been shown that this β 2GPI cleavage can alter binding to negative
427 surfaces and alter the role β 2GPI plays in plasminogen generation (12,49). However, its role in
428 autoantibody binding has not been assessed.
429

430 The structure of β 2GPI is somewhat controversial, Agar proposed a linear (J) and a circular (O)
431 form based on electron microscopy methods (1). More recently, other groups (3) have postulated that an S

432 form exists, though it has not been proven. Most recently the group of Pozzi have imaged β 2GPI after
433 molecular mutation to remove a disulphide bond in the 5th domain (DV) showing a difference in structure
434 (50). Finally, Buchholz et al. have shown structural change when lysines undergo post translational
435 modification *in vitro* resulting in an altering of the linear-circular equilibrium (9). However, all of these
436 modifications are *in vitro* and may not reflect exactly what occurs in patients. Plasmin cleavage has been
437 confirmed to occur *in vivo* and is theorised to occur more frequently within APS patients. Given the role
438 of clotting in disease progression and the role of β 2GPI in thrombosis and complement activation, which
439 has been shown to be required for clotting in APS patients (2) it is fair to suggest plasmin-clipped β 2GPI
440 does exist in APS patients *in vivo* and the lack of proof is a sign of the difficulties in assaying the
441 molecule.

442
443 This study is the first to apply biophysical and computational methods to plasmin-clipped β 2GPI
444 and has revealed a novel, potentially pathogenic structure of β 2GPI. Traditional structural biology
445 methods such as dynamic light scattering suggested a compact variant of the linear structure of β 2GPI
446 after plasmin cleavage. This was then corroborated by the SAXS analysis which highlighted structures
447 with smaller radius of gyration, and then revealed the S-shaped structure of plasmin-clipped β 2GPI
448 through fitting of the data to MD simulation structures. This structure was associated with an increased
449 ability to bind pathogenic autoantibodies from patients in serum as determined by ELISA, which has
450 never been described previously for plasmin-clipped β 2GPI.

451
452 The identified novel conformation may also explain the unusual functions of plasmin-clipped
453 β 2GPI. As discussed, plasmin-clipped β 2GPI can act as an inhibitor of angiogenesis. However, this
454 appears to be an enhancement of an inhibition activity already seen in the non-clipped β 2GPI. This
455 enhancement may be due to the change in structural distribution between linear and circular β 2GPI,
456 caused by plasmin cleavage. Reed's work on the potential for increased neonatal cardiac manifestations
457 showed that β 2GPI was able to bind and sequester Ro60 when in its non-cleaved form. However, the
458 cleaved peptide generated in plasmin-clipped β 2GPI (consisting of 8 amino acids) may contain the
459 sequence required for binding (17). This directly points at conformational change altering the function of
460 the protein. The effect of plasmin cleavage in cerebral infarct in APS patients is important as we have
461 shown increased binding of pathogenic antibodies to plasmin-clipped β 2GPI. The mechanism behind this
462 activity is incompletely understood with plasmin-clipped β 2GPI binding to Glu-plasminogen, whereas the
463 non-clipped β 2GPI cannot. This leads to decreased fibrinolysis and thus, increased clotting, and is
464 hypothesised to be through binding via the neutralised Lysine cluster generated by a structural change
465 first identified by Matsuura et al (51). This structural change in domain V is confirmed in our work with
466 the SAXS model showing significant change in domain V, including around the Lysine rich region.

467
468 To conclude, plasmin cleavage of β 2GPI resulted in a significant change in structure yielding a
469 novel S-shaped structure capable of increased antibody binding. This structure has increased flexibility
470 and fits well with the literature showing an altered activity in plasmin-clipped β 2GPI compared to healthy
471 control (non-clipped) β 2GPI. The demonstration of this new structure is an important step in
472 understanding the functions of β 2GPI within the body.

475 **Data Availability Statement** - All data are contained within this manuscript and data are available on
476 request.

477
478 **Ethics** – Research samples were collected by written informed consent (National Research Ethics
479 Committee- London Hampstead, reference number 12/LO/0373).

480
481 **Acknowledgements** - We thank Dr Felix Nagel for his insight in discussing the structure of β 2GPI during
482 this project, and Dr Nathan Cowieson and Nikul Khunti for excellent user support on Beamline B21 at
483 Diamond. We also thank Stephen McElvaney for his crucial role in logistical facilitation of this study. We
484 also thank Dr Valentina Spiteri for her invaluable insight during drafting.

485
486 **Author contributions** – T.C.R.M. conceived and coordinated the study, carried out the experiments, and
487 wrote the paper. H.B. recruited the patients and purified the cells and serum from them and conducted
488 Flow Cytometry experiments and analysis. C.L. helped perform the MD simulations and SAXS analyses.
489 X. G. assisted with the SAXS data collection. C.P. developed the original β 2GPI inhibition assays and
490 aided in their analysis. A.R. and I.G. provided the ethics permissions and patient samples. H.B. acquired
491 IMMS data under the supervision of K.T. S.J.P. oversaw the SAXS analysis and helped write the
492 manuscript. K.T., M.D. and P.A.D. helped with the study design, analytical development and manuscript
493 drafting.

494
495 **Funding and additional information** - We thank the Medical Research Foundation for a Fellowship to T.
496 C. R. M. (MRF-057-0004-RG-MCDO-C0800) and a Versus Arthritis Senior Fellowship
497 (ShS/SRF/22977). H.F.B. was supported by an UCB BIOPHARMA SPRL/BBSRC PhD Studentship
498 (BB/P504725/1). C.J.L. was supported by the EPSRC Centre for Doctoral Training in Emergent
499 Macromolecular Therapies (000033549) and IPSEN Bioinnovation (EP/L015218/1). S.J.P. was supported
500 by the CCP-SAS project, a joint EPSRC (EP/K039121/1) and NSF (CHE-1265821) grant. P.D is
501 supported by an EPSRC Grant (EP/P006485/1). Wellcome Collaborative Award in Science
502 (209250/Z/17/Z) to K.T.

503
504
505 **Conflict of interest** - The authors declare that they have no conflicts of interest with the contents of this
506 article. Dr McDonnell, Dr Pericleous, Prof. Giles and Prof. Rahman are inventors on a patent for Domain
507 I of a β 2GPI-based therapeutic.

508
509 **Abbreviations** - The abbreviations used are: β 2GPI, β 2 glycoprotein I; HC, healthy control; MD,
510 molecular dynamics; R_G , radius of gyration; SAXS, small angle X-ray scattering. IEX, Ion Exchange
511 Chromatography; ELISA, Enzyme Linked Immunosorbent Assay.

512
513 **ORCID identifiers** -

514 Thomas McDonnell 0000-0002-1712-9957,
515 Hannah Bradford 0000-0002-6827-3190,
516 Valentina A. Spiteri 0000-0002-5002-4989,
517 Christophe Lalaurie 0000-0002-2085-6362,
518 Xin Gao 0000-0003-0877-0643,
519 Charis Pericleous 0000-0001-8804-0493,
520 Anisur Rahman 0000-0003-2346-4484,
521 Ian Giles 0000-0001-8913-3894,
522 Stephen J. Perkins 0000-0001-9218-9805,
523 Mihaela Delcea 0000-0002-0851-9072,
524 Paul A. Dalby 0000-0002-0980-8167.

525 Konstantinos Thalassinos 0000-0001-5072-8428
526

References:

1. Agar, C., van Os, G. M., Mörgelin, M., Sprenger, R. R., Marquart, J. A., Urbanus, R. T., Derksen, R. H., Meijers, J. C., and de Groot, P. G. (2010) Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. *Blood* **116**, 1336-1343
2. McDonnell, T., Wincup, C., Buchholz, I., Pericleous, C., Giles, I., Ripoll, V., Cohen, H., Delcea, M., and Rahman, A. (2020) The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. *Blood Reviews* **39**, 100610
3. Pelkmans, L., and de Laat, B. (2012) Antibodies against domain I of β 2-glycoprotein I: the one and only? *Lupus* **21**, 769-772
4. de Laat, B., Derksen, R. H., van Lummel, M., Pennings, M. T., and de Groot, P. G. (2006) Pathogenic anti-beta2-glycoprotein I antibodies recognize domain I of beta2-glycoprotein I only after a conformational change. *Blood* **107**, 1916-1924
5. Schwarzenbacher, R., Zeth, K., Diederichs, K., Gries, A., Kostner, G. M., Laggner, P., and Prassl, R. (1999) Crystal structure of human beta2-glycoprotein I: implications for phospholipid binding and the antiphospholipid syndrome. *Embo j* **18**, 6228-6239
6. Hammel, M., Kriechbaum, M., Gries, A., Kostner, G. M., Laggner, P., and Prassl, R. (2002) Solution Structure of Human and Bovine β 2-Glycoprotein I Revealed by Small-angle X-ray Scattering. *Journal of Molecular Biology* **321**, 85-97
7. Ağar, Ç., van Os, G. M. A., Mörgelin, M., Sprenger, R. R., Marquart, J. A., Urbanus, R. T., Derksen, R. H. W. M., Meijers, J. C. M., and de Groot, P. G. (2010) β 2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. *Blood* **116**, 1336-1343
8. Buchholz, I., McDonnell, T., Nestler, P., Tharad, S., Kulke, M., Radziszewska, A., Ripoll, V. M., Schmidt, F., Hammer, E., Toca-Herrera, J. L., Rahman, A., and Delcea, M. (2021) Specific domain V reduction of beta-2-glycoprotein I induces protein flexibility and alters pathogenic antibody binding. *Scientific Reports* **11**, 4542
9. Buchholz, I., Nestler, P., Köppen, S., and Delcea, M. (2018) Lysine residues control the conformational dynamics of beta 2-glycoprotein I. *Phys Chem Chem Phys* **20**, 26819-26829
10. Kumar, S., Chinnaraj, M., Planer, W., Zuo, X., Macor, P., Tedesco, F., and Pozzi, N. (2021) An allosteric redox switch in domain V of β 2-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. *Journal of Biological Chemistry* **297**, 100890
11. Kumar, S., Wulf, J., 2nd, Basore, K., and Pozzi, N. (2023) Structural analyses of β (2)-glycoprotein I: is there a circular conformation? *J Thromb Haemost* **21**, 3511-3521
12. Bu, C., Gao, L., Xie, W., Zhang, J., He, Y., Cai, G., and McCrae, K. R. (2009) beta2-glycoprotein i is a cofactor for tissue plasminogen activator-mediated plasminogen activation. *Arthritis Rheum* **60**, 559-568
13. López-Lira, F., Rosales-León, L., Martínez, V. M., and Ruiz Ordaz, B. H. (2006) The role of beta2-glycoprotein I (beta2GPI) in the activation of plasminogen. *Biochim Biophys Acta* **1764**, 815-823
14. Sakai, T., Balasubramanian, K., Maiti, S., Halder, J. B., and Schroit, A. J. (2007) Plasmin-cleaved beta-2-glycoprotein 1 is an inhibitor of angiogenesis. *Am J Pathol* **171**, 1659-1669
15. Reed, J. H., Clancy, R. M., Purcell, A. W., Kim, M. Y., Gordon, T. P., and Buyon, J. P. (2011) β 2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. *J Immunol* **187**, 520-526
16. Yasuda, S., Atsumi, T., Ieko, M., Matsuura, E., Kobayashi, K., Inagaki, J., Kato, H., Tanaka, H., Yamakado, M., Akino, M., Saitou, H., Amasaki, Y., Jodo, S., Amengual, O., and Koike, T. (2004) Nicked β 2-glycoprotein I: a marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. *Blood* **103**, 3766-3772
17. Reed, J. H., Clancy, R. M., Purcell, A. W., Kim, M. Y., Gordon, T. P., and Buyon, J. P. (2011) β 2-glycoprotein I and Protection from Anti-SSA/Ro60-Associated Cardiac Manifestations of Neonatal Lupus. *The Journal of Immunology*, 1100122
18. Itoh, Y., Inuzuka, K., Kohno, I., Wada, H., Shiku, H., Ohkura, N., and Kato, H. (2000) Highly increased plasma concentrations of the nicked form of beta(2) glycoprotein I in patients with leukemia and with

577 lupus anticoagulant: measurement with a monoclonal antibody specific for a nicked form of domain V. *J*
578 *Biochem* **128**, 1017-1024

579 19. Bruschi, A. (2016) The Significance of Anti-Beta-2-Glycoprotein I Antibodies in Antiphospholipid Syndrome.
580 *Antibodies (Basel)* **5**

581 20. Pericleous, C., Ruiz-Limón, P., Romay-Penabad, Z., Marín, A. C., Garza-García, A., Murfitt, L., Driscoll, P. C.,
582 Latchman, D. S., Isenberg, D. A., Giles, I., Ioannou, Y., Rahman, A., and Pierangeli, S. S. (2015) Proof-of-
583 concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of
584 β 2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. *Rheumatology*
585 *(Oxford)* **54**, 722-727

586 21. Pericleous, C., Miles, J., Esposito, D., Garza-García, A., Driscoll, P. C., Lambrianides, A., Latchman, D.,
587 Isenberg, D., Rahman, A., Ioannou, Y., and Giles, I. (2011) Evaluating the conformation of recombinant
588 domain I of β (2)-glycoprotein I and its interaction with human monoclonal antibodies. *Mol Immunol* **49**,
589 56-63

590 22. McDonnell, T., Pericleous, C., Laurine, E., Tommasi, R., Garza-García, A., Giles, I., Ioannou, Y., and Rahman,
591 A. (2015) Development of a high yield expression and purification system for Domain I of Beta-2-
592 glycoprotein I for the treatment of APS. *BMC Biotechnol* **15**, 104

593 23. McDonnell, T. C. R., Willis, R., Pericleous, C., Ripoll, V. M., Giles, I. P., Isenberg, D. A., Brasier, A. R.,
594 Gonzalez, E. B., Papalardo, E., Romay-Penabad, Z., Jamaluddin, M., Ioannou, Y., and Rahman, A. (2018)
595 PEGylated Domain I of Beta-2-Glycoprotein I Inhibits the Binding, Coagulopathic, and Thrombogenic
596 Properties of IgG From Patients With the Antiphospholipid Syndrome. *Front Immunol* **9**, 2413

597 24. Willis, R., McDonnell, T. C. R., Pericleous, C., Gonzalez, E. B., Schleh, A., Romay-Penabad, Z., Giles, I. P.,
598 and Rahman, A. (2022) PEGylated Domain I of Beta-2-Glycoprotein I Inhibits Thrombosis in a Chronic
599 Mouse Model of the Antiphospholipid Syndrome. *Front Immunol* **13**, 842923

600 25. Albay, A., Artim-Esen, B., Pericleous, C., Wincup, C., Giles, I., Rahman, A., and McDonnell, T. (2019)
601 Domain I of β 2GPI is capable of blocking serum IgA antiphospholipid antibodies binding in vitro: an effect
602 enhanced by PEGylation. *Lupus* **28**, 893-897

603 26. Salmon, J. E., Girardi, G., and Holers, V. M. (2002) Complement activation as a mediator of
604 antiphospholipid antibody induced pregnancy loss and thrombosis. *Annals of the Rheumatic Diseases* **61**,
605 ii46

606 27. Pericleous, C., and Rahman, A. (2014) Domain I: the hidden face of antiphospholipid syndrome. *Lupus* **23**,
607 1320-1323

608 28. Cai, G., Guo, Y., and Shi, J. (1996) Purification of apolipoprotein H by polyethylene glycol precipitation.
609 *Protein Expr Purif* **8**, 341-346

610 29. Jo, S., Kim, T., Iyer, V. G., and Im, W. (2008) CHARMM-GUI: a web-based graphical user interface for
611 CHARMM. *J Comput Chem* **29**, 1859-1865

612 30. Jo, S., Cheng, X., Islam, S. M., Huang, L., Rui, H., Zhu, A., Lee, H. S., Qi, Y., Han, W., Vanommeslaeghe, K.,
613 MacKerell, A. D., Jr., Roux, B., and Im, W. (2014) CHARMM-GUI PDB manipulator for advanced modeling
614 and simulations of proteins containing nonstandard residues. *Adv Protein Chem Struct Biol* **96**, 235-265

615 31. Park, S.-J., Lee, J., Qi, Y., Kern, N. R., Lee, H. S., Jo, S., Joung, I., Joo, K., Lee, J., and Im, W. (2019) CHARMM-
616 GUI Glycan Modeler for modeling and simulation of carbohydrates and glycoconjugates. *Glycobiology* **29**,
617 320-331

618 32. Jo, S., Cheng, X., Lee, J., Kim, S., Park, S.-J., Patel, D. S., Beaven, A. H., Lee, K. I., Rui, H., Park, S., Lee, H. S.,
619 Roux, B., MacKerell, A. D., Jr., Klauda, J. B., Qi, Y., and Im, W. (2017) CHARMM-GUI 10 years for
620 biomolecular modeling and simulation. *Journal of computational chemistry* **38**, 1114-1124

621 33. MacKerell, A. D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J.,
622 Guo, H., Ha, S., Joseph-McCarthy, D., Kuchnir, L., Kuczera, K., Lau, F. T., Mattos, C., Michnick, S., Ngo, T.,
623 Nguyen, D. T., Prodhom, B., Reiher, W. E., Roux, B., Schlenkrich, M., Smith, J. C., Stote, R., Straub, J.,
624 Watanabe, M., Wiórkiewicz-Kuczera, J., Yin, D., and Karplus, M. (1998) All-atom empirical potential for
625 molecular modeling and dynamics studies of proteins. *J Phys Chem B* **102**, 3586-3616

- 626 34. Mackerell, A. D., Jr., Feig, M., and Brooks, C. L., 3rd. (2004) Extending the treatment of backbone
627 energetics in protein force fields: limitations of gas-phase quantum mechanics in reproducing protein
628 conformational distributions in molecular dynamics simulations. *J Comput Chem* **25**, 1400-1415
- 629 35. Steinbach, P. J., and Brooks, B. R. (1994) New spherical-cutoff methods for long-range forces in
630 macromolecular simulation. *Journal of Computational Chemistry* **15**, 667-683
- 631 36. Brooks, B. R., Brooks, C. L., 3rd, Mackerell, A. D., Jr., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis,
632 G., Bartels, C., Boresch, S., Caflisch, A., Caves, L., Cui, Q., Dinner, A. R., Feig, M., Fischer, S., Gao, J.,
633 Hodoscek, M., Im, W., Kuczera, K., Lazaridis, T., Ma, J., Ovchinnikov, V., Paci, E., Pastor, R. W., Post, C. B.,
634 Pu, J. Z., Schaefer, M., Tidor, B., Venable, R. M., Woodcock, H. L., Wu, X., Yang, W., York, D. M., and
635 Karplus, M. (2009) CHARMM: the biomolecular simulation program. *Journal of computational chemistry*
636 **30**, 1545-1614
- 637 37. Phillips, J. C., Hardy, D. J., Maia, J. D. C., Stone, J. E., Ribeiro, J. V., Bernardi, R. C., Buch, R., Fiorin, G.,
638 Hénin, J., Jiang, W., McGreevy, R., Melo, M. C. R., Radak, B. K., Skeel, R. D., Singharoy, A., Wang, Y., Roux,
639 B., Aksimentiev, A., Luthey-Schulten, Z., Kalé, L. V., Schulten, K., Chipot, C., and Tajkhorshid, E. (2020)
640 Scalable molecular dynamics on CPU and GPU architectures with NAMD. *The Journal of Chemical Physics*
641 **153**, 044130
- 642 38. Feller, S. E., Zhang, Y., Pastor, R. W., and Brooks, B. R. (1995) Constant pressure molecular dynamics
643 simulation: The Langevin piston method. *The Journal of Chemical Physics* **103**, 4613-4621
- 644 39. Martyna, G. J., Tobias, D. J., and Klein, M. L. (1994) Constant pressure molecular dynamics algorithms. *The*
645 *Journal of Chemical Physics* **101**, 4177-4189
- 646 40. Humphrey, W., Dalke, A., and Schulten, K. (1996) VMD: Visual molecular dynamics. *Journal of Molecular*
647 *Graphics* **14**, 33-38
- 648 41. Eldrid, C., Ben-Younis, A., Ujma, J., Britt, H., Cragnolini, T., Kalfas, S., Cooper-Shepherd, D., Tomczyk, N.,
649 Giles, K., Morris, M., Akter, R., Raleigh, D., and Thalassinos, K. (2021) Cyclic Ion Mobility–Collision
650 Activation Experiments Elucidate Protein Behavior in the Gas Phase. *Journal of the American Society for*
651 *Mass Spectrometry* **32**, 1545-1552
- 652 42. Eldrid, C., Ujma, J., Kalfas, S., Tomczyk, N., Giles, K., Morris, M., and Thalassinos, K. (2019) Gas Phase
653 Stability of Protein Ions in a Cyclic Ion Mobility Spectrometry Traveling Wave Device. *Anal Chem* **91**, 7554-
654 7561
- 655 43. Gabelica, V., Shvartsburg, A. A., Afonso, C., Barran, P., Benesch, J. L. P., Bleiholder, C., Bowers, M. T.,
656 Bilbao, A., Bush, M. F., Campbell, J. L., Campuzano, I. D. G., Causon, T., Clowers, B. H., Creaser, C. S., De
657 Pauw, E., Far, J., Fernandez-Lima, F., Fjeldsted, J. C., Giles, K., Groessl, M., Hogan, C. J., Jr., Hann, S., Kim,
658 H. I., Kurulugama, R. T., May, J. C., McLean, J. A., Pagel, K., Richardson, K., Ridgeway, M. E., Rosu, F.,
659 Sobott, F., Thalassinos, K., Valentine, S. J., and Wyttenbach, T. (2019) Recommendations for reporting ion
660 mobility Mass Spectrometry measurements. *Mass Spectrom Rev* **38**, 291-320
- 661 44. Weiss, T. M. (2016) Introduction to Small Angle X ray Scattering. BioSAXS Workshop, Online
- 662 45. Walker, K. T., Nan, R., Wright, D. W., Gor, J., Bishop, A. C., Makhatadze, G. I., Brodsky, B., and Perkins, S. J.
663 (2017) Non-linearity of the collagen triple helix in solution and implications for collagen function. *Biochem*
664 *J* **474**, 2203-2217
- 665 46. Iqbal, H., Fung, K. W., Gor, J., Bishop, A. C., Makhatadze, G. I., Brodsky, B., and Perkins, S. J. A solution
666 structure analysis reveals a bent collagen triple helix in the complement activation recognition molecule
667 mannan-binding lectin. *Journal of Biological Chemistry*
- 668 47. Buchholz, I., McDonnell, T., Nestler, P., Tharad, S., Kulke, M., Radziszewska, A., Ripoll, V. M., Schmidt, F.,
669 Hammer, E., Toca-Herrera, J. L., Rahman, A., and Delcea, M. (2021) Specific domain V reduction of beta-2-
670 glycoprotein I induces protein flexibility and alters pathogenic antibody binding. *Sci Rep* **11**, 4542
- 671 48. Hammel, M., Kriechbaum, M., Gries, A., Kostner, G. M., Laggner, P., and Prassl, R. (2002) Solution
672 structure of human and bovine beta(2)-glycoprotein I revealed by small-angle X-ray scattering. *J Mol Biol*
673 **321**, 85-97
- 674 49. Ohkura, N., Hagihara, Y., Yoshimura, T., Goto, Y., and Kato, H. (1998) Plasmin Can Reduce the Function of
675 Human β 2Glycoprotein I by Cleaving Domain V Into a Nicked Form. *Blood* **91**, 4173-4179

- 676 50. Kumar, S., Chinnaraj, M., Planer, W., Zuo, X., Macor, P., Tedesco, F., and Pozzi, N. (2021) An allosteric
677 redox switch in domain V of $\beta(2)$ -glycoprotein I controls membrane binding and anti-domain I
678 autoantibody recognition. *J Biol Chem* **297**, 100890
- 679 51. Matsuura, E., Inagaki, J., Kasahara, H., Yamamoto, D., Atsumi, T., Kobayashi, K., Kaihara, K., Zhao, D.,
680 Ichikawa, K., Tsutsumi, A., Yasuda, T., Triplett, D. A., and Koike, T. (2000) Proteolytic cleavage of $\beta 2$ -
681 glycoprotein I: reduction of antigenicity and the structural relationship. *International Immunology* **12**,
682 1183-1192

683

Figures




Figure 1: Production of plasmin clipped B2GPI. Batches of protein were cleaved and confirmed for cleavage by reduction SDS PAGE analysis. Whole B2GPI when reduced has reduced mobility on an SDS PAGE Gel (lane 3) however, after cleavage this reduced mobility is no longer seen (lane 5). Panel B shows the fluorescently labelled B2GPI and Plasmin clipped B2GPI by Native Gel with the lower smear of structures representing the plasmin clipped B2GPI and the higher smear representing non-clipped B2GPI. This was then probed with an anti-B2GPI antibody, showing specificity on the right, highlighting a different structure in Plasmin Clipped B2GPI




Figure 2: Altered Charge and Interactions. Plasmin cleavage removes the terminal 8 amino acids, leaving a truncated protein, the cleaved peptide being highlighted in red in panel A and C (surface model and ribbon model respectively). This peptide consists of 3 highly charged amino acids highlighted in panel B: one Lysine (Red) two Aspartic acids (Cyan), whilst also containing a cysteine which forms part of an allosteric disulphide with the neighbouring beta-sheet (yellow). The partner cysteine is internal to the structure, as such it has been highlighted in the ribbon model in yellow. Allosteric disulphides are associated with significant structural shift, as such the loss of the disulphide coupled with the alteration in local charge suggest it is likely B2GPI undergoes a significant structural change post plasmin cleavage.




Figure 3: Ion Mobility Mass Spectrometry and FACS analysis. Panel A shows the spectra of both the non-clipped B2GPI (top) and the plasmin clipped B2GPI (bottom), as can be seen both retain a number of glycoisoforms, however, the distribution of charge states is different in the Plasmin Clipped B2GPI suggesting a difference and a more compact conformation. Further to this in B, Ion Mobility data shows in non-clipped B2GPI that there two conformational families, with the dominant conformer corresponding to the earlier peak. In contrast plasmin clipped B2GPI shows a single dominant conformational family, suggesting that cleavage results in the loss of the extended form. Plasmin Clipped B2GPI is known to lose its ability to bind to cell surfaces, as such we conducted FACS with fluorescently labelled B2GPI (clipped and non-clipped) on HUVEC cells. As can be seen, non-clipped B2GPI (Cy5 labelled) bound to approximately 3-35% of cells (2ug B2GPI, 500,000 cells) whilst plasmin clipped B2GPI bound between 0 and 4.5% of cells, significantly less.




Figure 4: Activity and Structure. To test the activity of the plasmin clipped B2GPI vs the non clipped B2GPI we carried out competitive inhibitions using patient serum. Anti-B2GPI positive serum was pre-incubated with 20ug/ml of either Plasmin Clipped B2GPI or non-clipped B2GPI before exposure to a pre-coated B2GPI ELISA plate, a loss of binding to the plate was defined as an increase in inhibition by the in solution inhibitors. As can be seen in A, plasmin clipped B2GPI showed greater inhibition than non – clipped suggesting a different structure with a greater exposure of epitopes. Panel B shows the dynamic light scattering profile of both the plasmin clipped and non-clipped B2GPI, as can be seen the non-clipped B2GPI has a higher dynamic radius, suggesting a larger, defined structure whilst the clipped B2GPI shows a larger variation and a smaller size suggesting the structure of plasmin clipped B2GPI is more flexible, and smaller than non-clipped B2GPI.




Figure 5: Small Angle X-ray Scattering of Plasmin Clipped (Green) and Healthy Control (non-clipped) (Black) purified B2GPI. Plot A shows a Kratky plot of both proteins, the peaks are at a similar point suggesting they are both folded similarly, however, the green line maintaining a higher plateau may suggest increased flexibility in the Plasmin Clipped B2GPI. A normalised intensity plot (B) shows no significant difference between the proteins whilst the Guinier fitting (C) shows the $P(r)$ plot, with a characteristic high peak with extended tail shown in more rod shape structures, whilst the uneven shoulder shows the multi-domain nature of the protein. Panel D shows the Guinier fit whilst E shows a dimensionless Kratky plot, again the plasmin clipped has a more defined peak and trends above the healthy control (non-clipped) demonstrating the increased flexibility the cleavage facilitates.




Figure 6: Analysing the output from the SAXS data using Molecular Dynamics using >3000 individual frames, we identified the top 100 fits for each structure from their respective simulation. Plotting the Rg vs X^2 highlighted that the non clipped B2GPI had structures with a higher Rg (A,B). Further to this, visualising the structures in Pymol highlighted the plasmin clipped B2GPI has a significantly different structure, with the 1st 2 domains (DI, DII) rotated (C,D). Plotting the best fitting 100 frames for both non clipped and clipped B2GPI showed a significantly higher Rg for non-clipped compared to plasmin clipped (E) confirming what was seen by SDS PAGE and IMMS.




Figure 7: Alignment of the best fitting structures from the molecular dynamics simulations by domain IV (which shows the least difference) highlights the alterations in the orientation of DI and DII (A & B). When combining the top 100 frames of each of the clipped and non clipped B2GPI and conducting a PCA analysis, it shows that the two sets of structures are significantly different with PC1 accounting for almost 70% of differences whilst PC2 accounts for another 19% (C) with the black dots being plasmin clipped and the red dots non-clipped B2GPI, also showcasing the high variability in structures in the plasmin clipped compared to the non-clipped B2GPI. Finally two space models of the best fits are overlaid with the R39-G43 epitope highlights, as can be seen it not simply a case of the protein bending but in the plasmin clipped B2GPI it also rotates exposing the epitope differently, perhaps explaining the increased binding of antibodies in serum to the plasmin clipped B2GPI.




Figure 8: Molecular simulation of B2GPI. Panel A and B show the RMSD of non-clipped B2GPI across the simulation compared to plasmin clipped B2GPI (A) and the same comparison by amino acid (B). As can be seen in both measures plasmin clipped B2GPI has a far greater flexibility and movement suggesting a significant structural change occurs during cleavage. This corroborates the wet lab work suggesting a different structure and higher variation in structure. Further to this an analysis of intra-protein networking showed that significant differences were seen across multiple domains in the DCCM matrixes, this is demonstrated in (C) where sum differences in correlation per amino acid vs domains are plotted. As can be seen the red line (DI) shows the most significant changes in movement correlations with both itself and long range to DV, similar the yellow line (DII) shows significant alterations in correlation with the 3rd (DIII) and 4th (DIV) domain. A number of amino acids are picked out as high points for variation, pointing to a pathway throughout the protein effected by the modification. Plotting these variations on a heatmap for their correlation with other domains and themselves (D) reveals a backbone of amino acids which correlate with domains throughout the protein. Interestingly, significant alterations are seen in how these amino acids signal together, the green boxes show areas where correlations are altered, with more correlation between V132-V206 with DII in the Plasmin Clipped, whereas these are less strongly

corelated in the non-clipped model. Similarly, DI correlates with V19, 273 and 194 strongly in the non-clipped model but this is largely lost in the non-clipped model suggesting this long distance relationship is altered by clipping. The grouping of the amino acids themselves is changed too, with V11 clustering more with DI in the plasmin clipped model compared to the non-clipped which shows more correlation to later amino acids (V106-206). This lends credence to the idea that the cleavage of the terminal amino acids in Plasmin Clipped leads to an alteration in the movement of the 1st and 2nd domains (DI, DII), as seen in the previous experiments.